David A. Sallman, MD

Dr. David Sallman is a clinical instructor in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and II clinical trials) for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), based on the underlying mutational drivers of each disease.

Provider

David A. Sallman, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Hematology
  • Medical Oncology
  • Internal Medicine
FELLOWSHIP:
  • H. Lee Moffitt Cancer Center and Research Institute - Hematology/Oncology
RESIDENCY:
  • Massachusetts General Hospital - Internal Medicine
MEDICAL SCHOOL:
  • University of South Florida - MD
Provider

David A. Sallman, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Publications

  • Sallman DA, Lancet JE. What are the most promising new agents in acute myeloid leukemia?. Curr Opin Hematol. 2017 Mar;24(2):99-107. Pubmedid: 28030373.
  • Sallman DA, Komrokji R, List A, Padron E. Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'. Leukemia. 2017 Mar;31(3):767-768. Pubmedid: 27740632.
  • Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan;18(1):112-121. Pubmedid: 27927582.
  • Zhang L, McGraw KL, Sallman DA, List AF. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leuk Lymphoma. 2017 Aug;58(8):1777-1790. Pubmedid: 27967292.
  • Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther. 2016 Sep;9(3):89-95. Pubmedid: 27187622.
  • Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov;101(11):e457-e460. Pubmedid: 27418649.
  • Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar;30(3):666-673. Pubmedid: 26514544.
  • Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Front Oncol. 2016 Jun;6:151. Pubmedid: 27379212. Pmcid: PMC4909736.
  • Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec;128(25):2960-2975. Pubmedid: 27737891. Pmcid: PMC5179338.
  • McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug;101(8):e320-e323. Pubmedid: 27081179. Pmcid: PMC4967580.
  • McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Oct;6(33):34437-34445. Pubmedid: 26416416. Pmcid: PMC4741464.
  • Sallman DA, Padron E. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S50-S55. Pubmedid: 26297278.
  • Sallman DA, Wei S, List A. PP2A: The Achilles Heal in MDS with 5q Deletion. Front Oncol. 2014 Sep;4:264. Pubmedid: 25295231. Pmcid: PMC4172014.
  • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb;32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.
  • Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr;113(14):3226-3234. Pubmedid: 19075187. Pmcid: PMC2665892.
  • Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, Djeu JY. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther. 2007 Nov;6(11):2938-2947. Pubmedid: 18025278.
  • Patterson S, Wei S, Chen X, Sallman D, Gilvary D, Zhong B, Pow-Sang J, Yeatman T, Djeu J. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene. 2006 Nov;25(45):6113-6122. Pubmedid: 16652143.

Provider

David A. Sallman, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 18876
A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in Combination with Cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome with Wild-Type TP53
Condition: Malignant Hematology
Intervention: ALRN-6924; Cytarabine (Cytosine Arabinoside)
Open

CLINICAL TRIAL 18382
A Phase 1 Study of KB003 in Patients with Previously Treated Chronic Myelomonocytic Leukemia (CMML)
Condition: Malignant Hematology
Intervention: KB003
Open

CLINICAL TRIAL 17929
A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: BI 836858
Open

CLINICAL TRIAL 18390
A Phase 1 Dose Escalation, Multicenter, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 In Patients With Relapsed or Refractory Hematologic Malignancies
Condition: Malignant Hematology
Intervention: FT-1101
Open

CLINICAL TRIAL 17865
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition: Malignant Hematology
Intervention: SL-401
Open

CLINICAL TRIAL 18083
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m^2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m^2 SC/IV daily for 3 days every month) versus Azcitidine (AZA; 75 mg/m^2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent
Condition: Malignant Hematology
Intervention: azacitidine (5-azacitidine); decitabine (5-aza-2'-deoxycytidine)
Open

CLINICAL TRIAL 18815
A Phase 2 Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia
Condition: Malignant Hematology
Intervention: Zarnestra (tipifarnib); tipifarnib
Open

CLINICAL TRIAL 18406
A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: AZD1775; Belinostat; MK-1775 (AZD1775); PXD101 (Belinostat)
Open

CLINICAL TRIAL 18772
A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Condition: Malignant Hematology
Intervention: Durvalumab; MEDI4736 (Durvalumab); azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18901
A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line Lower (Low and intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Condition: Malignant Hematology
Intervention: OPN-305; azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18939
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Condition: Malignant Hematology
Intervention: H3B-8800
Open

CLINICAL TRIAL 18521
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications
Condition: Multiple Myeloma
Intervention: Abiraterone acetate; Dexamethasone; KPT-8602; Zytiga (Abiraterone acetate)
Open

CLINICAL TRIAL 19136
Randomized Phase II Study To Assess The Role Of Nivolumab As Single Agent To Eliminate Minimal Residual Disease And Maintain Remission In Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

David A. Sallman, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio